source
- FDA provides minimal comment on Grail cancer test before advisory committee meetingThe FDA typically releases briefing documents that give a clear stance on a drug or diagnostic's safety and efficacy before its advisory committee convenes. In the upcoming meeting concerning Grai…
- Sleuth predicts surge in Western licensing of Chinese radioligand therapies by 2027Sleuth, a biopharma intelligence platform, says that while Chinese radiopharmaceutical assets have seen few licensing deals so far, the market is set to change. The firm notes that China now runs…